Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (FLGT) delivers innovative genetic testing and diagnostic solutions through its dual focus on clinical laboratory services and oncology therapeutic development. This news hub provides investors and healthcare professionals with timely updates on the company’s financial performance, scientific advancements, and strategic initiatives.
Access authoritative reporting on earnings announcements, regulatory milestones, and partnership developments alongside analysis of FLGT’s expanding test menu and cancer research programs. Our curated news collection enables efficient tracking of operational updates across both laboratory services and drug development segments.
Key content includes coverage of diagnostic technology innovations, clinical trial progress, and healthcare collaborations that shape FLGT’s position in precision medicine. All materials are vetted for relevance to investment analysis and clinical practice trends.
Bookmark this page for streamlined access to Fulgent Genetics’ latest corporate developments, with new content added as official announcements are released through regulatory channels and company communications.
Fulgent Genetics has been awarded a contract by the CDC to conduct ongoing genomic sequencing of SARS-CoV-2 samples using its Next Generation Sequencing (NGS) capabilities. This partnership aims to facilitate a large-scale genomic survey of the virus, crucial for understanding transmission patterns and identifying emerging variants. The CDC's initiative is expected to enhance public health responses to COVID-19. Fulgent's expertise in COVID-19 testing solutions positions it as a key player in this critical research effort.
Fulgent Genetics (NASDAQ: FLGT) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. The company's executives, including Chairman and CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis, will host a presentation at 8:40 a.m. ET.
A live webcast of the event will be accessible via the Investor Relations section of Fulgent Genetics' website.
Fulgent Genetics, Inc. (NASDAQ: FLGT) reported record fourth quarter 2020 results with revenue of $295.0 million, a remarkable 3,400% increase year-over-year. The company achieved GAAP income of $166.3 million or $6.16 per share. Full-year revenue was $421.7 million, up 1,200% from 2019. Looking ahead to 2021, Fulgent anticipates overall revenue of approximately $800.0 million, reflecting a 90% growth. Non-COVID revenue grew 43% in Q4, and the company continues to expand its testing capabilities and customer base.
Fulgent Genetics (NASDAQ: FLGT) announced it will release its Q4 and full-year 2020 financial results on March 4, 2021, after market close. The company's CEO Ming Hsieh and other executives will host a conference call to discuss the results at 4:30 PM ET (1:30 PM PT). Investors can access the call via a live audio webcast or by dialing (855) 321-9535 with conference ID 7669989. A replay will be available until March 11, 2021.
Fulgent's technology platform offers comprehensive testing solutions, including SARS-CoV-2 detection tests, with Emergency Use Authorization from the FDA.
Fulgent Genetics (NASDAQ: FLGT) has announced that its CFO, Paul Kim, and CCO, Brandon Perthuis, will present virtually at the H.C. Wainwright BIOCONNECT 2021 Conference from January 11-14, 2021. A webcast of the presentation will be available at 6:00 a.m. ET on January 11 on the company’s Investor Relations page and accessible for 90 days. Fulgent Genetics specializes in comprehensive testing solutions and has launched various tests for SARS-CoV-2, receiving Emergency Use Authorization from the FDA for its RT-PCR tests.
Fulgent Genetics (Nasdaq: FLGT) has been awarded a contract to continue providing COVID-19 testing for NYC public schools through the end of the 2021 school year. The partnership, established following a competitive selection process, will deploy Fulgent's FDA EUA-approved RT-PCR tests, ensuring results within 24 hours. The testing will utilize a less invasive nasal swab method for students and staff. This extension underscores Fulgent's proven capabilities, with significant positive feedback on its testing process, which is highly scalable and efficient.
Fulgent Genetics (NASDAQ: FLGT) announced participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The company’s top executives, including CEO Ming Hsieh and CFO Paul Kim, will engage in a pre-recorded fireside chat, which will be accessible via their Investor Relations webpage for 90 days post-conference. Fulgent Genetics specializes in comprehensive testing solutions, notably in genetic testing and COVID-19 detection, emphasizing high accuracy, competitive turnaround times, and customizable testing options through their advanced technology platform.
Fulgent Genetics (NASDAQ: FLGT) has revised its 2020 revenue guidance to at least $300 million, a significant increase of 28% from the prior estimate of $235 million. This marks over 800% growth year-over-year, driven by rising demand for COVID-19 testing as cases surge across the U.S. The company reports a testing capacity exceeding 60,000 tests per day, positioning it to meet growing market needs effectively. Fulgent's advanced technology platform supports a broad test menu, including RT-PCR tests for SARS-CoV-2, receiving Emergency Use Authorization from the FDA.
Fulgent Genetics (NASDAQ:FLGT) has partnered with the Los Angeles Network for Enhanced Services (LANES) and the LA County Department of Health Services to expedite the sharing of COVID-19 test results from nearly 20 local testing sites. This initiative aims to improve patient care through rapid access to test data, which is essential as COVID-19 cases surge in LA County. Since May 25, Fulgent has been conducting thousands of tests daily, facilitating electronic sharing of results to inform healthcare providers. The partnership enhances healthcare response by integrating test results into electronic health records within 24 hours.
Fulgent Genetics (NASDAQ: FLGT) announced that CFO Paul Kim and CCO Brandon Perthuis will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 11, 2020, at 3:30 p.m. ET. A live webcast of the presentation will be accessible on the company’s Investor Relations website.
The company offers comprehensive testing solutions, including its proprietary technology platform for genetic testing and COVID-19 detection, supported by Emergency Use Authorization from the FDA for its RT-PCR tests and at-home testing services.
FAQ
What is the current stock price of Fulgent Genetics (FLGT)?
What is the market cap of Fulgent Genetics (FLGT)?
